Nkarta Stifel 2026 Virtual Immunology and Inflammation Forum

There we go. Yes, he's on my cell phone.

Nadir, do you want to give a little brief overview?

Yeah. Hopefully everyone can hear my voice here. Apologies that we couldn't be on video. There were a little technical difficulties. As an overview, Nkarta is an autoimmune disease company. We're developing a CD19 target CAR natural killer cell for autoimmune diseases. The cell is allogeneic off-the-shelf. We are administering outpatient, and this is in indications across two company-sponsored INDs. First one, ENTRUST. There we go.

First one is Ntrust-1. We just lost him. By the way, this is part of his CEO training, how to deal with audio-visual problems when they happen.

How you doing? The first is Ntrust-1, which is in lupus nephritis, and the second is Ntrust-2, which is a basket study, which has scleroderma, myositis, vasculitis, and now rheumatoid arthritis.

As you know, we have upcoming data at ACR. Hold on a second. Okay, you're back?

Yes. Okay. I just- It's okay.

Okay. All right, I just went through Ntrust-1 and Ntrust-2, so you can take it from there.

How's that? Okay. The idea here is to look at this potential cell therapy and what we've really seen from the autologous CAR T space, but really deliver this potential therapeutic benefit to patients in a therapy that is readily available off the shelf, on demand, with incredible safety profile that can make it more amenable and more accessible to a broader range of patients.

We are looking forward to presenting our first set of data at the ACR Convergence 2026 meeting in November of this year.

Also to have the ability to redose if it's needed. One of the things we keep hearing from investors now is how safe are your cells, because of all the safety issues that we've been hearing about, and then can you retreat, and can you retreat with lymphodepletion? What you'll see is, yes, we can. We've done that in oncology. We're now doing it in autoimmunity, and we're actually seeing similar results that we saw in oncology. We'll be presenting those data either at the plenary session, not the plenary, but the oral presentations at ACR or at the company event, which we will hold at ACR as well, where we'll explain all the data that we have.

Okay. What we think we have is a safe cell, an effective cell, and one that can be retreated if needed, which is important for patients, because it's difficult to retreat with autologous CAR Ts, et cetera.